RxDoctor Payments Data

Brian Weiss

Pediatric Hematology-Oncology · Indianapolis, INNPI 1033274840

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $1,314 of the $1,439 with a category attached, or 91.3%. F. Hoffmann-la Roche AG accounts for 91.3% of it on its own, with 1 other manufacturer making up the rest.

$1,439in general payments, 2019–2025

Across 6 payments — averaging $239.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • F. Hoffmann-la Roche AG$1K
  • AbbVie$125
$979,666in research payments, 2019–2025

Across 31 payments — averaging $31,602 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$569K
  • Novartis$349K
  • Eli Lilly$34K
  • Genentech, Inc.$18K
  • Lantheus Medical Imaging, Inc.$7K
  • F. Hoffmann-la Roche AG$3K

What the payments were for

  • Speaking & faculty fees$1,31491%
  • Food & beverage$1259%

General payments by program year

19
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
F. Hoffmann-la Roche AG5$1,314
AbbVie1$125

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,439 in reported general payments places this provider in the 70th percentile of 59 pediatric hematology-oncology providers in Indiana.

See all pediatric hematology-oncology providers in Indiana

Other pediatric hematology-oncology in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →